If you liked this article you might like

2 'Swing for the Fences' Small Biotechs
Surveying the NASH Drug Landscape
Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers
Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views